Health care stocks were flat to lower pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.
Revvity (RVTY) shares were down more than 9% after the company reported lower fiscal Q2 adjusted earnings and cut its fiscal 2025 non-GAAP EPS guidance.
Celcuity (CELC) stock was up more than 230% after the company said a phase 3 trial of its drug gedatolisib, combined with fulvestrant, with and without palbociclib, demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in a type of breast cancer.
BeOne Medicines (ONC) stock was up more than 2% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Tevimbra for treating adults with resectable non-small cell lung cancer at high risk of recurrence.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。